Onconova Therapeutics, Inc. (NASDAQ: ONTX) Starts Presentation at 30th Annual ROTH Conference
Onconova Therapeutics (NASDAQ: ONTX) is a phase 3 clinical-stage biopharmaceutical company engaged in the discovery and development of novel small molecule drug candidates to treat cancer. The company’s primary focus is on myelodysplastic syndromes (MDS). Its lead candidate, Rigosertib, is a proprietary phase 3 small molecule agent that the company believes is able to block cellular signaling by targeting RAS effector pathways. Utilizing a proprietary chemistry platform, Onconova has developed a pipeline of targeted agents that are designed to work against specific cellular pathways important in cancer cells. The company currently has three product candidates in the clinical stage and…







